Predicting early relapse in lung cancer patients after surgery
Utilizing Perioperative Variation Trends of Circulating Tumor Cells and Tumor Pathological Characteristics as a Combined Relapse Prediction Model for Resectable Non-Small Cell Patients - a Prospective Clinical Feasibility Trial
This study is testing a new way to predict early relapse in lung cancer patients after surgery by looking at changes in their tumor cells and seeing if giving them chemotherapy helps improve their outcomes.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 358 (estimated) |
| Ages | 20 Years to 90 Years |
| Sex | All |
| Sponsor | Chang Gung Memorial Hospital Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Taoyuan City) |
| Trial ID | NCT06262386 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to develop a combined relapse prediction model for patients with resectable non-small cell lung cancer who have undergone tumor resection. The study focuses on identifying patients at risk of early relapse by analyzing circulating tumor cells (CTCs) and their behavior post-surgery. By monitoring changes in CTC levels within the first three days after surgery, the trial seeks to improve early detection of potential relapses, which could lead to better patient management and outcomes. The intervention involves administering cisplatin-based chemotherapy to eligible participants.
Who should consider this trial
Good fit: Ideal candidates for this study are patients with resectable non-small cell lung cancer who have undergone tumor resection and are at clinical stage 1a to 3a.
Not a fit: Patients with pathologic stage greater than 3b or those who cannot complete treatment or provide blood samples for CTC analysis may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a reliable method for early detection of relapse in lung cancer patients, potentially improving survival rates.
How similar studies have performed: While studies have explored the role of circulating tumor cells in cancer relapse, this specific approach to predicting early relapse in resectable lung cancer is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients who presented with resectable disease ( Clinical stage 1a to 3a) 2. Patients who received tumor resection Exclusion Criteria: 1. Pathologic stage greater than stage 3b or 4 2. Pathologic stage less than stage 1a1 3. Could not complete treatment course 4. Could not receive blood sampling for CTC (circulating tumor cell) or regular surveillance
Where this trial is running
Taoyuan City
- Ching-Yang Wu — Taoyuan City, Taiwan (Recruiting)
Study contacts
- Principal investigator: Ching-Yang Wu — Chang Gung Memorial Hospital
- Study coordinator: Ching-Yang Wu
- Email: wu.chingyang@gmail.com
- Phone: +886975368204
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.